Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction

"Patients were treated with one cycle of Tislelizumab 200 mg monotherapy on day~1\. At 3 weeks and with intervals of 3 weeks between each cycle (weeks 3, 6, 9 and 12), patients received a total of four combination cycles consisting of Tislelizumab 200 mg, docetaxel 50 mg m-2 and oxaliplatin 100 mg m-2 intravenously at the beginning of each cycle, plus oral capecitabine 850 mg m-2 twice daily on days 1-14 of each cycle."